NCT03610061 2024-04-12
RaDD
Austin Health
Phase 1 Completed
Clinical Trials
10 trialsNCT03310619 2024-04-04
PLATFORM
Celgene
Phase 1/2 Completed
NCT02733042 2023-11-18
FUSION NHL 001
Celgene
Phase 1/2 Completed
NCT03003520 2023-05-22
A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma
Celgene
Phase 2 Completed
NCT02706405 2022-08-24
JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Fred Hutchinson Cancer Center
Phase 1 Terminated
NCT03685344 2021-10-26
Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma
ADC Therapeutics S.A.
Phase 1 Terminated
NCT02401048 2019-06-27
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas
Pharmacyclics LLC.
Phase 1/2 Completed
NCT02549651 2019-02-27
MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)
MedImmune LLC
Phase 1 Completed
NCT03241017 2018-04-09
IDA-D
Insel Gruppe AG, University Hospital Bern
Phase 2 Withdrawn
NCT02205333 2017-06-28
MEDI6469
MedImmune LLC
Phase 1/2 Terminated